1801.HK in “China Becomes Pharma's Global R&D Engine”
Innovent Biologics, Inc.
Its broad oncology and metabolic pipeline offers multiple opportunities for overseas licensing and commercialization.
1801.HK impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 1801.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 1801.HK impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 247 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Its broad oncology and metabolic pipeline offers multiple opportunities for overseas licensing and commercialization.
Read the full China Becomes Pharma's Global R&D Engine storyBull side
3 stories- America Imports the World's Drug Prices
1801.HK in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Innovent's portfolio of lower-cost biosimilars in oncology and immunology can support payer demands for credible alternatives to expensive biologic brands.
- GLP-1 Eats Everything
1801.HK in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Innovent commercializes mazdutide, an approved GLP-1/glucagon dual agonist for chronic weight management in China.
- Viewing
1801.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Its broad oncology and metabolic pipeline offers multiple opportunities for overseas licensing and commercialization.
Bear side
0 storiesNo bear-side stories for 1801.HK yet.